Form 4: Apellis Pharmaceuticals General Counsel Sells 5,000 Shares

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock at a price of $34.235 per share on December 11, 2024.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, sold 5,000 shares of the company's common stock on December 11, 2024.
• The sale price was $34.235 per share.
• Following the transaction, Mr. Watson directly owns 112,721 shares of Apellis common stock.
• He also indirectly owns 3,333 shares through a custodial account for his son, 70,136 shares through The David O. Watson Irrevocable Trust of 2023, and 6,667 shares through The Watson Education Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a routine Form 4 filing, which is required when company insiders trade shares. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the United States.
• The sale of shares by a company officer is a common occurrence and does not necessarily indicate a negative outlook for the company.
• Similar filings are made by officers of comparable companies such as Regeneron, Biogen, and Vertex Pharmaceuticals when they trade their company's stock.

Stakeholder Impact

• The sale of shares by a company officer may be of interest to shareholders, but it is a common occurrence and does not necessarily indicate a negative outlook for the company.

Key Dates

Keywords

Apellis Pharmaceuticals, David O. Watson, stock sale, insider trading, common stock, beneficial ownership, Form 4